ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1083

Comparison of a Handheld Ultrasound Device with Cart-Based Ultrasound for the Assessment of Gout Lesions in People with Established Gout

Rachel Murdoch1, Lene Terslev2, Julia Martin3, Borislav Mihov1, Gregory Gamble1, Søren Torp-Pedersen4, Anne Horne1 and Nicola Dalbeth1, 1University of Auckland, Auckland, New Zealand, 2Rigshospitalet-Glostrup & COPECARE, Glostrup, Denmark, 3Te Whatu Ora Te Toka Tumai, Auckland, New Zealand, 4Rigshospitalet, Copenhagen, Denmark

Meeting: ACR Convergence 2024

Keywords: Crystal-induced arthritis, gout, Ultrasound

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Ultrasound is frequently used in rheumatology practice to assist with the diagnosis of rheumatic and musculoskeletal diseases. In patients with gout, it allows visualization of monosodium urate (MSU) crystal deposition as double contour, aggregates and tophus. Use of handheld portable ultrasound is increasing and would improve access for people with rheumatic disease when conventional, cart-based ultrasound is unavailable. This study compared handheld and cart-based ultrasound for the assessment of gout lesions in people with established gout.

Methods: The lower limbs of 21 participants with gout (mean duration of gout 12 years, 90% on urate-lowering therapy, mean serum urate 0.34 mmol/L) were independently scanned at six sites (1st and 2nd metatarsophalangeal joints, knee, patellar ligament, Achilles tendon, and peroneal tendons) using cart-based (LOGIQ P9) and handheld (Vscan AirTM) ultrasound by two rheumatologists. One rheumatologist was randomized to scan the right or left leg first with the cart-based or handheld ultrasound. The other rheumatologist scanned the legs in the opposite order with the imaging devices reversed. Images were saved and blinded images assessed by two rheumatologists experienced in gout ultrasound for the presence of double contour, tophus, erosion and aggregates using OMERACT definitions.

Results: A total of 41 limbs in 21 participants were scanned. On handheld ultrasound, 19/21 (90%) of participants had at least one site with double contour, tophus and erosions, and 21/21 (100%) had at least one site with aggregates. There were similar findings using cart-based ultrasound. However, site-level inter-device analysis showed only fair-good agreement: kappa (percentage agreement) for double contour 0.22 (67%), tophus 0.46 (77%), erosion 0.63 (83%) and aggregates 0.37 (75%) (Table 1). There were more aggregates detected by cart-based ultrasound in joints and more tophi detected by handheld ultrasound in ligaments and tendons (data not shown).

Conclusion: Handheld ultrasound can detect gout lesions in people with established gout and has potential value in assisting with identification of gout lesions in patients who do not have access to cart-based ultrasound.  However, concordance between cart-based and handheld ultrasound in detection of some gout lesions is low, particularly double contour and aggregates.

Supporting image 1

Table 1. Site-level analysis. Number (%) of sites with gout lesions on ultrasound and inter-device agreement.


Disclosures: R. Murdoch: None; L. Terslev: Eli Lilly, 6, Janssen, 1, 6, Novartis, 6, Pfizer, 6, Speakers feeJanssen, Novartis, Pfizer, UCB and GE healthcare, 6, UCB, 1; J. Martin: None; B. Mihov: None; G. Gamble: None; S. Torp-Pedersen: None; A. Horne: None; N. Dalbeth: Arthrosi, 2, AstraZeneca, 5, 6, Avalo Therapeutics, 2, Dexcel Pharma, 2, Hikma, 6, Horizon, 2, 6, JPI, 2, JW Pharmaceutical Corporation, 2, LG Chem, 2, Novartis, 6, PK Med, 2, Protalix, 2, PTC Therapeutics, 2, Selecta, 2, Shanton Pharma, 2, Sobi, 2, Unlocked Labs, 2.

To cite this abstract in AMA style:

Murdoch R, Terslev L, Martin J, Mihov B, Gamble G, Torp-Pedersen S, Horne A, Dalbeth N. Comparison of a Handheld Ultrasound Device with Cart-Based Ultrasound for the Assessment of Gout Lesions in People with Established Gout [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/comparison-of-a-handheld-ultrasound-device-with-cart-based-ultrasound-for-the-assessment-of-gout-lesions-in-people-with-established-gout/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparison-of-a-handheld-ultrasound-device-with-cart-based-ultrasound-for-the-assessment-of-gout-lesions-in-people-with-established-gout/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology